- TheStreet.com•24 days ago
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
- Insider Monkey•last month
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) recently took the opportunity at the American Headache Society meeting in San Diego to present data from clinical trials of its compound ALD403. The compound is being developed as a drug for treating migraines. Alder presented data relating to Phase 2b and Phase 1 trials of ALD403. It also outlined the […]
Alder Biopharmaceuticals Inc.NasdaqGM
After hours: 27.060.00 (0.00%) as of 5:01 PM EDT
|Bid||26.40 x 200|
|Ask||39.32 x 500|
|52wk Range||15.82 - 48.50|
|Day's Range||26.83 - 27.87|
|Avg Vol (3m)||673,468|
As of 4:00 PM EDT. Market closed.